Biotech Startups
9,920 companies tagged Biotech, with their investors and founders.
Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD. Its programs aim to clear disease-driving proteins like toxic TDP43 to slow disease progression for patients and their families.
2 investors
Dxcover provides a platform for rapid development of liquid biopsies to detect cancer and other diseases.
2 investors
Dynamic Biosensors develops the heliX biosensor instruments and switchSENSE and single-cell Interaction Cytometry (scIC) technologies for characterizing molecule-molecule and molecule-cell interactions and binding kinetics. Its instruments serve researchers in drug discovery and life sciences studying biophysical molecular interactions; the company was acquired by Bruker in 2024.
2 investors
2 investors
Ecovative grows whole-cut meat alternatives and leather-like materials from mycelium using its AirMycelium indoor cultivation platform, which integrates with existing mushroom farming infrastructure. Its products include MyBacon, a sliceable vegan bacon sold in over 3,000 US retail stores, and Forager, a mycelium-based leather substitute in development for fashion and electronics brands.
2 investors
Eden Bio develops machine-learning technology for genetic engineering and protein yield optimization across food, pharmaceutical, and biofuel industries. The company supports customers through precision fermentation to enable sustainable production processes.
2 investors
Eden Brew develops food and supplementation products designed to deliver nutrition in natural forms that align with how the human body processes nutrients, with a focus on sustainable scaling and long-term health support.
2 investors
Edesa Biotech is a clinical-stage biopharmaceutical company developing monoclonal antibody candidates as host-directed therapeutics for inflammatory and immune-related diseases. Its pipeline targets conditions such as Acute Respiratory Distress Syndrome (ARDS) by modulating immune pathways implicated across multiple diseases.
2 investors
Edgewise Therapeutics develops precision therapeutics for serious cardiovascular disease.
2 investors
Editas Medicine develops gene editing medicines using CRISPR/Cas9 and CRISPR/Cas12a technology to treat serious diseases including blood disorders, cardiovascular conditions, and cancer. The company focuses on in vivo genome editing approaches and serves patients worldwide with transformative, precision genomic medicines.
2 investors
Edity develops an AI-powered platform that engineers therapeutic proteins and uses immune cells (such as T-cells and NK cells) as carriers to deliver them to diseased tissues. Its plug-and-play technology is compatible with allogeneic approaches and aimed at creating new modalities for intracellular therapy.
2 investors
Egle Therapeutics develops targeted immunotherapy drugs by leveraging regulatory T cell (Treg) biology to treat autoimmune diseases and cancer. The company creates drug candidates that selectively modulate Tregs to inhibit them in tumors or expand them in inflamed tissues.
2 investors
2 investors
Eigen develops co-therapies that modulate cancer cell target expression to improve the effectiveness of targeted treatments such as antibody-drug conjugates and radioligand therapies. It uses a discovery platform combining machine learning, robotic automation, and high-throughput combinatorial screening to design combination therapies addressing tumor heterogeneity.
2 investors
2 investors
2 investors
Eirion Thera develops therapeutics focused on aesthetic medicine and medical dermatology. It operates in the biotech and pharmaceutical sector targeting dermatological and aesthetic conditions.
2 investors
electroCore develops non-invasive vagus nerve stimulation (nVNS) medical devices, marketed as gammaCore, to treat patients suffering from pain and chronic conditions. The company operates in the bioelectronic medicine field and sells its products in markets including the US, UK, EU countries, Canada, Australia, New Zealand, and Saudi Arabia.
2 investors
Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases. Its drug is designed to combine with existing DMARDs for patients who have an inadequate response to standard treatments like methotrexate and TNF inhibitors.
2 investors
Eleven Therapeutics develops mRNA therapeutics by combining synthetic chemistry with AI, using massively-parallel processes to map RNA chemical space and determine structure-activity relationships. The platform optimizes RNA molecules for safety, efficiency, and duration of effect.
2 investors
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation. The protein has also shown regenerative effects in preclinical models of aging-related cardiovascular, neurological, metabolic, pulmonary, renal, and skeletal muscle conditions.
2 investors
Elicit Plant develops crop treatments based on phytosterols, natural plant growth regulators that strengthen plants' natural defense mechanisms and improve crop resilience for agricultural use. The company runs applied research combining controlled germination and cultivation chamber experiments with field trials, and operates internationally beyond its French base.
2 investors
Eliksa Therapeutics develops innovative treatments for rare diseases with unmet medical needs.
2 investors
Clinical-stage biotech developing next-generation polyene antifungals for life-threatening invasive fungal infections.
2 investors